HC Wainwright Rates Gain Therapeutics (GANX) buy, $8 Price Target
HC Wainwright maintains its bullish stance on Gain Therapeutics with an $8 price target, a 294.09% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Gain Therapeutics, Inc. ($GANX) "buy" with a $8 price target on July 1, 2026.
Since the rating, $GANX is down 10.1% after 1 week, down 15.6% after 1 month and down 36.7% to date (from the $1.99 close on Jul 1, 2026).
GANX
Gain Therapeutics, Inc.
Key Points
- HC Wainwright reiterated its Buy rating on Gain Therapeutics, setting a price target of $8 on July 1, 2026.
- HC Wainwright's $8 price target implies 294.09% upside from Gain Therapeutics, Inc.'s ($GANX) current $2.03 share price.
- Gain Therapeutics traded at $2.03 on NasdaqGM with a market cap of approximately $86.6 million.
- Multiple insiders purchased shares, and institutional activity showed mixed changes in holdings.
Get $GANX trade alerts by text
We text you when insiders, Congress or big funds trade $GANX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Gain Therapeutics, Inc. alert may contain errors. Disclosures
HC Wainwright has reiterated its Buy rating on Gain Therapeutics, Inc. (NasdaqGM: GANX), maintaining a price target of $8. This reaffirmation came on July 1, 2026, with analyst Raghuram Selvaraju expressing continued confidence in the company's prospects.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Gain Therapeutics
Marshall Wace, LLP increased its holdings by 107,495 shares, bringing its total to 1,769,788 shares valued at about $3.43 million. Meanwhile, Potomac Capital Management, Inc. slightly reduced its position by 1,400 shares, ending with 1,008,600 shares worth approximately $1.96 million. Jones Financial Companies LLLP cut its stake by 70,598 shares, leaving it with 631,615 shares valued at $1.16 million. On the other hand, Geode Capital Management, LLC added 49,400 shares, totaling 447,342 shares valued at $868,527. Cambridge Investment Research Advisors, Inc. and DME Capital Management, LP maintained their positions.
Gain Therapeutics, Inc. Stock Up 15.3%
Shares of Gain Therapeutics traded near $2.03 on Wednesday. The company has a market cap of roughly $86.6 million. It operates in the biotechnology sector and has a beta of 0.164, suggesting lower volatility compared to the broader market. The stock's 52-week range spans from $1.41 to $4.34, with a 50-day moving average of $1.83 and a 200-day moving average of $2.20. The company holds a strong liquidity position, with a current ratio of 4.69 and a quick ratio of 4.51, although it has a debt-to-equity ratio of 4.8.
$GANX price target
Gain Therapeutics, Inc. daily closes and this analyst's $8 target. Not advice.
Insider Buying and Selling at Gain Therapeutics, Inc.
On March 24, 2026, CEO Gene Mack purchased 200,000 shares, while Gianluca Fuggetta acquired 50,000 shares. These transactions were not under a prearranged trading plan. Earlier, on June 24, 2025, several insiders, including Jeffrey Scott Riley, Eric Richman, Claude Nicaise, and Khalid Islam, each bought 15,000 shares.
Analysts Set New Price Targets
On July 1, 2026, HC Wainwright & Co. reiterated its Buy rating on Gain Therapeutics, setting an $8 price target. The consensus among analysts is a Buy rating, with a mean target price of $7.20, based on five analyst opinions.
About Gain Therapeutics
Gain Therapeutics, Inc. is a biotechnology company based in Bethesda, Maryland. It focuses on developing small molecule therapeutics to treat various diseases, including Parkinson's and Alzheimer's. The company's Magellan drug discovery platform identifies novel allosteric binding sites, aiming to modulate protein function to address disease causes. Founded in 2017, Gain Therapeutics is led by CEO Gene Mack and employs about 20 people.
Bottom Line
HC Wainwright's reaffirmation of its Buy rating reflects ongoing confidence in Gain Therapeutics' potential, despite the stock's current trading price. Investors and analysts closely watch the company's innovative approach in biotechnology. Insider purchases and varied institutional activity highlight continued interest in the company's future prospects.
Related Filing Alerts
Source: HC Wainwright's rating change on $GANX (Jul 1, 2026). Written by software, not financial advice. How we make alerts